Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies into Earlier Lines of Care

EP. 1: Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies into Earlier Lines of Care

ByBinod Dhakal, MD, MS,Carol Ann Huff, MD,Prerna Mewawalla, MD

June 29th 2026

Experts unpack earlier use of BCMA bispecific antibodies in relapsed myeloma, guiding second-line choices, sequencing, and real-world safety management.

EP. 2: Defining Anti-CD38 Refractory Disease in Relapsed/Refractory Multiple Myeloma

ByBinod Dhakal, MD, MS,Carol Ann Huff, MD,Prerna Mewawalla, MD

June 29th 2026

Learn how clinicians define daratumumab refractoriness vs exposure and why the 60-day rule guides smarter second-line myeloma choices.

Trending on CancerNetwork

Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines

Generic Enzalutamide Receives Tentative FDA Approval in Prostate Cancer

40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study